Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnsen
BACKGROUND: Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. Consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the Calgary Depression Scale for Schizophrenia sum score in patients within the schizophrenia spectrum...
April 22, 2023: Journal of Clinical Psychopharmacology